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ABSTRACT
Background: There is no single test currently available, which can predict respiratory failure in patients with 
amyotrophic lateral sclerosis (ALS) with high sensitivity and specificity. This study explores the potential use of 
transcutaneous carbon dioxide (PtcCO2) monitoring in early detection of respiratory failure in ALS.
Methods: This is a prospective observational cohort study consisting of 50 consecutive patients with ALS. The 
participants underwent 3 monthly assessments for symptoms of respiratory failure, forced vital capacity (FVC) and 
PtcCO2 monitoring. Once respiratory failure was clinically suspected by the treating physician, further follow-up was 
stopped. The presence of respiratory failure was confirmed with an overnight capnometry.
Results: Symptoms of respiratory failure were the most powerful tool, alerting the physician to the possibility of 
respiratory failure. All the patients where respiratory failure was confirmed on overnight capnometry had symptoms of 
respiratory failure. 37% of these patients had FVC of > 50% predicted and only 13% had daytime hypercapnia. None 
of the patients had daytime hypercapnia without any other marker of respiratory failure. There was statistically 
significant difference between the day time PtcCO2 and median overnight PtcCO2 (p=0.0002).
Conclusions: This study has emphasised the importance of symptom history as a screening tool to suspect respiratory 
failure in ALS. Once again, the limitations of FVC in predicting respiratory failure is demonstrated in this study. A normal 
daytime PtcCO2 may be falsely reassuring and day time hypercapnia is a late finding which implies established 
respiratory failure.
KEY WORDS: Amyotrophic lateral sclerosis Neuromuscular respiratory failure Transcutaneous partial pressure of 
carbon dioxide
O R I G I N A L  A R T I C L E
INTRODUCTION: 
Regularly screening for evidence of respiratory failure is 
an important facet in the management of amyotrophic 
lateral sclerosis (ALS)1. Currently there is no single test 
which can predict respiratory failure with high sensitivity 
and specificity. Moreover, no test of respiratory muscle 
strength has significant positive predictive power to 
predict hypercapnia in the ALS patients with significant 
bulbar weakness2. Standard current practice is to 
screen patients for symptoms of respiratory failure and 
supplement this with one or more respiratory function 
tests. Forced vital capacity (FVC) is the most commonly 
used respiratory function test in many ALS clinics for 
this purpose. ALS patients with respiratory failure can 
benefit from non-invasive ventilation (NIV) which has 
been shown to improve survival as well as quality of 
life3. Although the precise timing for NIV initiation for 
maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
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Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
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Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
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* Values only available for 12 patients
Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
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* Values only available for 12 patients
Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
* Values only available for 12 patients
Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
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late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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maximum benefit has not been established in a clinical 
trial, once a patient with ALS reaches the stage of 
respiratory failure the average survival is only few 
months without respiratory support. Therefore, for 
important prognostic and therapeutic implications early 
detection of respiratory failure is important. Since the 
first ever manifestation of impaired ventilation is 
nocturnal hypercapnia, a simple and non-invasive test 
to monitor partial pressure of carbon dioxide in the 
blood on a regular basis would be very useful in clinical 
practice4. The transcutaneous carbon dioxide (TOSCA) 
monitor allows transcutaneous measurement of the 
partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the 
ear lobe5. To our knowledge, there are currently no 
studies on the potential benefit of transcutaneous 
carbon dioxide monitoring to screen for respiratory 
failure in patients with ALS. We hypothesized that if 
PtcCO2 is recorded at regular intervals during follow up 
clinical assessments, it may help in the early diagnosis 
of respiratory failure.
MATERIAL AND METHODS
Study design: This is a prospective observational 
cohort study consisting of 50 consecutive ALS patients.
Aims of the Study: This study aims to determine 
whether PtcCO2 is a sensitive test for screening for 
early type II respiratory failure compared to symptom 
history or FVC.
Research Hypothesis: Periodic measurement of 
PtcCO2 in the clinic, using this non-invasive method 
may help in the early detection of type II respiratory 
failure in patients with ALS. We hypothesized that 
during the follow-up assessments we will identify some 
patients with a raised PtcCO2 (and hence respiratory 
failure) but otherwise having no symptoms of 
respiratory failure and a preserved FVC. This may allow 
us to conclude that periodic recording of PtcCO2 in 
otherwise asymptomatic patients is potentially a useful 
measure for early detection of respiratory failure in both 
limb and bulbar onset ALS.
Standard protocol approval, registration and 
patient consent: The study protocol was approved by 
Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained 
from all patients (or carers of patients) participating in 
the study. 
Study setting and population: The study was carried 
out at the Sheffield care and research centre for motor 
neurone disorders. In this clinic patients with ALS are 
routinely screened for respiratory impairment. A cohort 
of 50 consecutive patients with ALS, who gave 
informed consent, was recruited irrespective of the 
duration of their disease. The exclusion criteria were 
presence of respiratory failure and inability (due to 
mental capacity) or unwillingness to give informed 
consent. 
Study tools:  Transcutaneous carbon dioxide level 
(PtcCO2) was recorded using TOSCA 500, operated in 
accordance with the manufacturer’s operating manual. 
A disposable ear clip was used to attach the sensor 
from the TOSCA monitor to the ear lobe. A contact gel 
was applied between the sensor and the skin to 
facilitate diffusion. The device was operated on a 
“QUICKSTART” mode which warms the sensor to a 
temperature of 42°C (increasing the arterial blood 
supply in the dermal capillary bed below the sensor) 
and gives the reading in 10-15 minutes. In order to 
have a consistent approach in screening for symptoms 
of respiratory failure, a questionnaire consisting of 18 
possible symptoms of respiratory insufficiency was 
designed. A detailed search of the literature did not 
identify any pre-existing questionnaire which could be 
used for this purpose. The questionnaire was based on 
symptoms reported by patients with respiratory muscle 
weakness (in the literature and clinical experience of 
the investigators)6-12. It was interviewer administered 
and took 5-10 minutes to complete. The symptoms 
were divided into three domains i.e., breathing related 
symptoms, sleep related symptoms and 
mental/emotional state. This format was partially 
influenced by the format of the ALS functional rating 
scale and sleep apnoea quality of life index13 14. Each 
question was answered as yes or no, with one mark 
awarded for each affirmative answer. The questionnaire 
was piloted to ensure the questions were easy to 
understand, clear and open ended. The questionnaire 
in Table 1 is the final questionnaire developed following 
some minor amendments in response to the pilot 
experience. A volumetric spirometer (vitalograph® – 
Alpha) was used to record FVC. A face mask was used 
for the patients not able to achieve a tight mouth seal. 
The spirometer was calibrated daily and the best of 
three attempts was recorded. 
Measurements: On the registration visit, after 
obtaining an informed consent patients underwent the 
following assessments: 
1. Detailed questioning about the symptoms of   
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) 
were recruited. At each 3 monthly subsequent visits 
patients underwent the following assessments:
1. Detailed questioning about the symptoms of        
    respiratory failure (using a standard questionnaire)
2. TOSCA PtcCO2
3. FVC
Once clinically suspected by the treating physician, 
respiratory failure was confirmed by overnight 
capnometry (using TOSCA500), at which point the 
study-specific respiratory assessments were stopped.
Table 1 Screening questionnaire to identify 
potential patients with respiratory failure
RESULTS 
The characteristics of study participants are 
summarised in Table 2. The average age was 60 years, 
58% were male and participants were predominantly 
sporadic ALS with limb onset disease. The mean 
duration between disease onset and study entry was 
39 months. 30 patients reached the primary end point. 
8 patients died during follow-up without been 
diagnosed with respiratory failure and 6 patients were 
lost to follow-up during the course of the study. 6 
patients have not reached the primary end point at the 
time of writing and are likely to be slow progressing 
atypical forms of ALS. Although we hypothesised that 
recording transcutaneous PCO2 would be particularly 
valuable for patients with poor bulbar function, only 6 
patients with severe bulbar dysfunction could be 
recruited during the recruitment time available. 
en trials of this test performed namely MIND 
ALERTNESS in which the participants were directed to 
play a video game in which he/she had to recognize the 
direction of the arrows in a given time. 
Table 2: Baseline characteristics of the study 
participants
Evidence of respiratory failure
Table 3 summarises the respiratory parameters at the 
time when respiratory failure was suspected by the 
clinician and confirmed with an overnight capnometry. 
These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict 
respiratory failure. FVC and daytime PtcCO2 were 
insensitive as FVC of > 70% of predicted and daytime 
PtcCO2 of < 5.0 kPa was observed in patients where 
respiratory failure was suspected clinically due to 
presence of symptoms and those who fulfilled the 
criteria of respiratory failure on nocturnal capnometry 
(median PtcCO2 ≥ 6 kPa).
Table 3: Respiratory parameters when respiratory 
failure suspected and confirmed by overnight 
capnometry
* Values only available for 12 patients
Symptoms of respiratory failure
The most common symptoms (present in at least 1/3rd 
of the patients at the time of suspected respiratory 
failure) are reported in table 4. These questions may 
assist in identifying those at risk and in the decision to 
investigate a patient further.  Cronbach’s alpha (α) was 
calculated as a measure of internal consistency of the 
responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 
30 patients was 0.7. A Cronbach’s α value between 0.7 
and 0.8 is considered as having a strong and positive 
correlation of the items of a scale.
Table 4: Most common sympztoms at the 
ztime of suspected respiratory failure 
Relationship between symptoms and daytime 
carbon dioxide level
Figure 1 illustrates the relationship between the 
symptoms of respiratory failure and daytime PtcCO2. 
The study was not powered for such analysis and hence 
within the limits of small number of patients no 
relationship between the symptoms of respiratory 
failure and daytime PtcCO2 is demonstrated at any of 
the follow-up time points.
Relationship between daytime and nocturnal 
carbon dioxide levels
Nocturnal transcutaneous capnometry was carried out 
when respiratory failure was clinically suspected. The 
difference between daytime PtcCO2 and median 
overnight PtcCO2 was statistically significant 
(p=0.0002). Figure 2 illustrates the Bland-Altman plot 
used for the analysis of agreement between the two 
methods. Pearson correlation coefficient was 0.656.
DISCUSSION
A crucial aspect in the management of patients with 
ALS early identification of respiratory compromise. 
Respiratory muscle weakness is often unmasked during 
sleep, particularly during rapid eye movement (REM) 
sleep when the intercostal and accessory muscles of 
breathing are inactive and the diaphragm carries the 
work of breathing9. A weak diaphragm may fail to allow 
adequate ventilation and frequent arousals are required 
as a compensatory mechanism to maintain adequate 
ventilation, thus reducing total sleep time, REM sleep 
and the overall quality of sleep. Hence disturbed sleep, 
due to episodes of hypoventilation, is one of the earliest 
manifestations of respiratory insufficiency and usually 
occurs well before daytime hypoventilation and the 
resulting daytime hypercapnia develops9. The 
symptoms of “sleep fragmentation” include nocturia, 
nightmares, unrefreshing sleep and daytime 
somnolence. Symptoms of CO2 retention include 
morning headaches, poor appetite, fatigue, cognitive 
dysfunction and, as a result, poor quality of life. With 
disease progression, patients may develop exertional 
dyspnoea, orthopnoea, dyspnoea at rest and anxiety 
associated with the feeling of breathlessness1. 
In order to objectively assess respiratory function, a 
variety of invasive and non-invasive, voluntary and 
involuntary respiratory function tests have been 
assessed to identify patients with respiratory 
impairment and plan timely intervention. However, no 
single respiratory test can reliably confirm or exclude 
the presence of nocturnal hypoventilation. An FVC of 
50% predicts day time hypercapnia with a sensitivity of 
53% and specificity of 89%2, demonstrating the 
limitations of this test for predicting even late 
respiratory failure. Moreover, it is a volitional test which 
is often difficult for the patients with severe bulbar 
dysfunction to perform. The most appropriate method 
to screen for respiratory failure in such patients remains 
unclear. The ideal test would be non-invasive, easy to 
perform in an out-patient setting and would diagnose 
early respiratory failure with high sensitivity. This study 
was planned with the aim to evaluate the value of 
regular transcutaneous carbon dioxide measurements 
in the early detection of respiratory failure. It is 
non-invasive and independent of the subject being 
tested and findings are easy to interpret (PCO2 > 6.0 
kPa = respiratory failure). Although daytime 
hypercapnia is reported in the literature as a relatively 
late event15 16, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically 
assessed previously. There are a number of important 
lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not 
have been clinically suspected using other parameters. 
In the current cohort, no patient was identified to be in 
respiratory failure on the basis of daytime PtcCO2 alone. 
Most patients (87%) with other features of respiratory 
failure and nocturnal hypercapnia, had a normal 
daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary 
activation of accessory muscles of breathing and 
enhanced activation of the respiratory center as a result 
of improved blood biochemistry. The accessory muscle 
of respiration and central respiratory drive are both 
suppressed during normal sleep9. Hence, daytime 
normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of 
symptom history is highlighted in this study. In all the 
patients who reached the primary endpoint, 
development of symptoms of respiratory compromise 
alerted the physicians to the presence of respiratory 
insufficiency. The most common symptoms identified 
are listed in Table 4. Based on the most common 
symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed 
in Table 4. The resultant questionnaire, with a certain 
cut-off score, is likely to have a strong positive 
predictive value in diagnosing respiratory failure. 
However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger 
sample size17. A difficulty in this regard is in deciding 
which comparator to use as benchmark of respiratory 
failure. The best definition of early respiratory failure in 
patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least nocturnal 
transcutaneous capnography, which is time consuming 
and expensive. Hence, bedside respiratory function 
tests need to be combined with clinical assessment to 
select appropriate patients who are most likely to have 
nocturnal hypercapnia and may benefit from 
intervention with NIV. Once again, the limitations of FVC 
in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal 
hypercapnia had an FVC of greater than 70% predicted. 
One patient with an FVC of 95% predicted had 6 
symptoms of respiratory failure with a median nocturnal 
PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% 
predicted was not associated with any symptoms of 
respiratory failure. In conclusion, regular PtcCO2 
measurements may not help in early identification of 
respiratory failure and daytime normocapnia may be 
falsely reassuring. Special attention should be given to 
the presence of symptoms of respiratory failure and 
overnight capnography carried out where clinical 
suspicion of respiratory failure is high. Demonstration of 
nocturnal hypoventilation (rising PCO2 and falling 
SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV. 
Figure 1: Relationship between number of 
symptoms and PtcCO2
Figure 2: Bland-Altman plot of the difference 
between the nocturnal and day time PCO2 against 
the average of the two measurements
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